New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 13, 2013
06:47 EDTSIGA, PIPCritics question SIGA Technologies smallpox deal, NY Times says
The U.S. has agreed to buy $463M of a new smallpox vaccine from Siga Technologies (SIGA), and began taking delivery of the treatment this week, according to The New York Times. The deal has stirred controversy, as some say the government is paying far too much for the drug and has ordered too much of it, the newspaper stated. Reference Link
News For SIGA;PIP From The Last 14 Days
Check below for free stories on SIGA;PIP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 17, 2014
19:47 EDTSIGASIGA Technologies receives bankruptcy court approval for first-day motions
Subscribe for More Information
September 16, 2014
09:25 EDTPIP, SIGAOn The Fly: Pre-market Movers
Subscribe for More Information
06:51 EDTSIGASIGA Technologies files petition for relief to supply Tecovirimat
Subscribe for More Information
September 11, 2014
07:25 EDTPIPAegis to hold a conference
Subscribe for More Information
September 10, 2014
09:07 EDTPIPPharmAthene awarded $28.1M contract by NIAID
Subscribe for More Information
September 9, 2014
09:08 EDTPIPPharmAthene presented non-clinical animal data on SparVax anthrax vaccine
PharmAthene announced that recent non-clinical animal data from its SparVax anthrax vaccine program were presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, or ICAAC, in Washington, DC. In a poster presentation Dr. Sherry Crowe, Director, Immunology for PharmAthene, presented an overview of non clinical animal studies of SparVax showing, among other things, that it can induce dose-dependent protective immunity in the established rabbit model for inhalational anthrax, and was statistically non-inferior to the currently licensed anthrax vaccine, BioThrax, when comparing survival and toxin neutralization assay results from the nonclinical anthrax aerosol challenge model.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use